OptimizeRX (OPRX) PT Raised to $16 at Stifel

Stifel analyst David Grossman raised the price target on OptimizeRX (NASDAQ: OPRX) to $16.00 (from $12.00) while maintaining a Buy rating.

The analyst commented, “Last week, we hosted CEO Steve Silvestro and CFO Ed Stelmakh at Stifel's CSI Conference. Management expanded on many key themes from the 1Q earnings report including improving DTC (Medicx) performance and its importance to OPRX's overall value proposition, secular demand drivers, higher subscription content and Improving visibility. While there is still work to be done, we are encouraged by many of the changes underway, including heightened focus on financial guidance/performance.”

You May Also Be Interested In

• BofA Securities Downgrades PagSeguro (PAGS) to Neutral
• Guggenheim Reiterates Buy Rating on Netflix (NFLX)
• Bank of America (BAC) PT Raised to $69 at Wells Fargo